IL148360A0 - A herpes viral mutant and pharmaceutical compositions containing the same - Google Patents

A herpes viral mutant and pharmaceutical compositions containing the same

Info

Publication number
IL148360A0
IL148360A0 IL14836000A IL14836000A IL148360A0 IL 148360 A0 IL148360 A0 IL 148360A0 IL 14836000 A IL14836000 A IL 14836000A IL 14836000 A IL14836000 A IL 14836000A IL 148360 A0 IL148360 A0 IL 148360A0
Authority
IL
Israel
Prior art keywords
same
pharmaceutical compositions
compositions containing
herpes viral
viral mutant
Prior art date
Application number
IL14836000A
Other languages
English (en)
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of IL148360A0 publication Critical patent/IL148360A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
IL14836000A 1999-08-31 2000-02-02 A herpes viral mutant and pharmaceutical compositions containing the same IL148360A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15162199P 1999-08-31 1999-08-31
PCT/US2000/002409 WO2001016331A1 (en) 1999-08-31 2000-02-02 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression

Publications (1)

Publication Number Publication Date
IL148360A0 true IL148360A0 (en) 2002-09-12

Family

ID=22539547

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14836000A IL148360A0 (en) 1999-08-31 2000-02-02 A herpes viral mutant and pharmaceutical compositions containing the same
IL148360A IL148360A (en) 1999-08-31 2002-02-25 Mutant of herpes virus and pharmaceuticals containing it

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148360A IL148360A (en) 1999-08-31 2002-02-25 Mutant of herpes virus and pharmaceuticals containing it

Country Status (14)

Country Link
EP (1) EP1212428B1 (ja)
JP (1) JP4551042B2 (ja)
KR (1) KR100701905B1 (ja)
AT (1) ATE283921T1 (ja)
AU (1) AU781219B2 (ja)
CA (1) CA2383372C (ja)
DE (1) DE60016429T2 (ja)
ES (1) ES2233349T3 (ja)
IL (2) IL148360A0 (ja)
MX (1) MXPA02002142A (ja)
PT (1) PT1212428E (ja)
SI (1) SI1212428T1 (ja)
WO (1) WO2001016331A1 (ja)
ZA (1) ZA200202413B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
EP1486212A1 (en) * 2000-06-01 2004-12-15 Sloan-Kettering Institute For Cancer Research Combination of a mutant herepes virus and irinotecan for the treatment of cancer
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
EP1694852B1 (en) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
US8945531B2 (en) 2010-02-19 2015-02-03 The University Of Tokyo Recombinant herpes virus and pharmaceutical composition containing the same
EP3011964A1 (en) * 2014-10-24 2016-04-27 Karcinolys Compounds and associations for treating pancreatic cancer
US20190328783A1 (en) * 2016-04-15 2019-10-31 Cellectis A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
EP3429633B1 (en) 2016-04-15 2021-02-24 Cellectis A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
CN116135972A (zh) * 2021-11-16 2023-05-19 中国科学院深圳先进技术研究院 基于中国hsv临床分离株的溶瘤病毒及其构建方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
WO1998042195A1 (en) * 1997-03-27 1998-10-01 University Of Cincinnati Replication-competent herpes simplex viruses

Also Published As

Publication number Publication date
PT1212428E (pt) 2005-03-31
EP1212428B1 (en) 2004-12-01
WO2001016331A1 (en) 2001-03-08
KR100701905B1 (ko) 2007-04-02
CA2383372C (en) 2010-04-13
DE60016429T2 (de) 2005-11-24
AU781219B2 (en) 2005-05-12
KR20020092905A (ko) 2002-12-12
ATE283921T1 (de) 2004-12-15
IL148360A (en) 2007-12-03
ZA200202413B (en) 2003-06-25
CA2383372A1 (en) 2001-03-08
DE60016429D1 (de) 2005-01-05
AU3477400A (en) 2001-03-26
EP1212428A1 (en) 2002-06-12
ES2233349T3 (es) 2005-06-16
JP2003508055A (ja) 2003-03-04
SI1212428T1 (en) 2005-06-30
JP4551042B2 (ja) 2010-09-22
MXPA02002142A (es) 2003-04-10

Similar Documents

Publication Publication Date Title
AU690733B2 (en) Genetic therapy of vascular diseases with a cell-specific active substance which is dependent on the cell cycle
IL148360A0 (en) A herpes viral mutant and pharmaceutical compositions containing the same
GR3033909T3 (en) Cytosine deaminase negative selection system for gene transfer techniques and therapies.
IL124411A0 (en) Lipopolyamines as transfection agents and pharmaceutical uses thereof
CA2182303A1 (fr) Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
AU1458395A (en) Composition containing nucleic acids, preparation and uses
HK1033956A1 (en) Genetically modified tumor-targeted bacteria with reduced virulence
AU681705B2 (en) Endosomolytically active particles
GB2338484B (en) Medicaments comprising a nucleic acid encoding a cell targeting moiety and a prodrug activating enzyme
AU4180996A (en) Suicide genes and combinations of pyrimidine nucleoside and nucleobase analogues with suicide genes for gene therapy
HU9403343D0 (en) New pharmaceutical uses of krill enzymes
EP1471926B8 (en) Compositions and methods for the therapeutic use of an atonal-associated sequence
AU2002212505A1 (en) Dna expression vectors
GB9618477D0 (en) Gene therapy
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
AU5318496A (en) Adenovirus vectors for gene therapy
AU6120600A (en) Herpes simplex virus expressing foreign genes and method for treating cancers therewith
EP1070122A4 (en) INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES
MX9806041A (es) Proteina purificada sr-p70.
MY126526A (en) Pharmaceutical formulations
HUP0105208A2 (hu) Génterápiás alkalmazások
DK0925064T3 (da) 5-Androsten-3-beta,17-alpha-diol som inhibitor for tumorvækst
AU2003232336A1 (en) Plasmid stabilisation in vivo
AU4216599A (en) Hematopoietic progenitor cell gene transduction
MX9705959A (es) Formulaciones para il-12.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed